A novel druggable DYRK3/CAMKV signaling module for Neuroblastoma tumor growth inhibitionEsteban J. Rozen(University of Massachusetts Chan Medical School), Jason M. Shohet(University of Massachusetts Chan Medical School)bioRxiv (Cold Spring Harbor Laboratory)December 1, 202310.1101/2023.11.30.569438Cited by 0SaveCiteExport RISWatch citationsRelated PapersMYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma|Oncotarget|2018|39A Novel Druggable Dual-Specificity tYrosine-Regulated Kinase3/Calmodulin Kinase-like Vesicle-Associated Signaling Module with Therapeutic Implications in Neuroblastoma|Biomedicines|2024|2